Literature DB >> 31462446

Prenatal Opioid Exposure: Neurodevelopmental Consequences and Future Research Priorities.

Elisabeth Conradt1, Tess Flannery2, Judy L Aschner3,4, Robert D Annett5, Lisa A Croen6, Cristiane S Duarte7,8, Alexander M Friedman9, Constance Guille10, Monique M Hedderson6, Julie A Hofheimer11, Miranda R Jones12, Christine Ladd-Acosta12,13, Monica McGrath12, Angela Moreland14, Jenae M Neiderhiser15, Ruby H N Nguyen16, Jonathan Posner8, Judith L Ross17, David A Savitz18, Steven J Ondersma19, Barry M Lester20,21.   

Abstract

Neonatal opioid withdrawal syndrome (NOWS) has risen in prevalence from 1.2 per 1000 births in 2000 to 5.8 per 1000 births in 2012. Symptoms in neonates may include high-pitched cry, tremors, feeding difficulty, hypertonia, watery stools, and breathing problems. However, little is known about the neurodevelopmental consequences of prenatal opioid exposure in infancy, early childhood, and middle childhood. Even less is known about the cognitive, behavioral, and academic outcomes of children who develop NOWS. We review the state of the literature on the neurodevelopmental consequences of prenatal opioid exposure with a particular focus on studies in which NOWS outcomes were examined. Aiming to reduce the incidence of prenatal opioid exposure in the near future, we highlight the need for large studies with prospectively recruited participants and longitudinal designs, taking into account confounding factors such as socioeconomic status, institutional variations in care, and maternal use of other substances, to independently assess the full impact of NOWS. As a more immediate solution, we provide an agenda for future research that leverages the National Institutes of Health Environmental Influences on Child Health Outcomes program to address many of the serious methodologic gaps in the literature, and we answer key questions regarding the short- and long-term neurodevelopmental health of children with prenatal opioid exposure.
Copyright © 2019 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2019        PMID: 31462446      PMCID: PMC6759228          DOI: 10.1542/peds.2019-0128

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   9.703


  73 in total

1.  Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy.

Authors:  Viveka Sundelin Wahlsten; Ihsan Sarman
Journal:  Acta Paediatr       Date:  2013-03-20       Impact factor: 2.299

Review 2.  Neonatal abstinence syndrome.

Authors:  Mara G Coyle; Susan B Brogly; Mahmoud S Ahmed; Stephen W Patrick; Hendrée E Jones
Journal:  Nat Rev Dis Primers       Date:  2018-11-22       Impact factor: 52.329

3.  Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes.

Authors:  R E Johnson; H E Jones; D R Jasinski; D S Svikis; N A Haug; L M Jansson; W B Kissin; G Alpan; M E Lantz; E J Cone; D G Wilkins; A S Golden; G R Huggins; B M Lester
Journal:  Drug Alcohol Depend       Date:  2001-06-01       Impact factor: 4.492

4.  Child neuroanatomical, neurocognitive, and visual acuity outcomes with maternal opioid and polysubstance detoxification.

Authors:  Kristine B Walhovd; Astrid Bjørnebekk; Kristin Haabrekke; Torill Siqveland; Kari Slinning; Egil Nygaard; Anders M Fjell; Paulina Due-Tønnessen; Atle Bjørnerud; Vibeke Moe
Journal:  Pediatr Neurol       Date:  2014-11-26       Impact factor: 3.372

5.  Behavioural concomitants of prenatal addiction to narcotics.

Authors:  M E Strauss; R H Starr; E M Ostrea; C J Chavez; J C Stryker
Journal:  J Pediatr       Date:  1976-11       Impact factor: 4.406

6.  The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age.

Authors:  Daniel S Messinger; Charles R Bauer; Abhik Das; Ron Seifer; Barry M Lester; Linda L Lagasse; Linda L Wright; Seetha Shankaran; Henrietta S Bada; Vincent L Smeriglio; John C Langer; Marjorie Beeghly; W Kenneth Poole
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

7.  Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes.

Authors:  Karol Kaltenbach; Kevin E O'Grady; Sarah H Heil; Amy L Salisbury; Mara G Coyle; Gabriele Fischer; Peter R Martin; Susan Stine; Hendrée E Jones
Journal:  Drug Alcohol Depend       Date:  2018-02-01       Impact factor: 4.492

8.  Educational Disabilities Among Children Born With Neonatal Abstinence Syndrome.

Authors:  Mary-Margaret A Fill; Angela M Miller; Rachel H Wilkinson; Michael D Warren; John R Dunn; William Schaffner; Timothy F Jones
Journal:  Pediatrics       Date:  2018-09       Impact factor: 7.124

9.  Vagal tone regulation during sustained attention in boys exposed to opiates in utero.

Authors:  J E Hickey; P E Suess; D B Newlin; L Spurgeon; S W Porges
Journal:  Addict Behav       Date:  1995 Jan-Feb       Impact factor: 3.913

Review 10.  Early life stress and environmental influences on the neurodevelopment of children with prenatal opioid exposure.

Authors:  Elisabeth Conradt; Sheila E Crowell; Barry M Lester
Journal:  Neurobiol Stress       Date:  2018-08-15
View more
  29 in total

1.  Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome.

Authors:  Adam J Czynski; Jonathan M Davis; Lynne M Dansereau; Barbara Engelhardt; Peter Marro; Debra L Bogen; Mark L Hudak; Jeffrey Shenberger; Elisha M Wachman; Erica L Oliveira; Barry M Lester
Journal:  J Pediatr       Date:  2020-01-24       Impact factor: 4.406

2.  Prenatal opioid exposure inhibits microglial sculpting of the dopamine system selectively in adolescent male offspring.

Authors:  Caroline J Smith; Tania Lintz; Staci D Bilbo; Elena H Chartoff; Madeline J Clark; Karen E Malacon; Alia Abiad; Nicholas J Constantino; Veronica J Kim; Young C Jo; Yanaira Alonso-Caraballo
Journal:  Neuropsychopharmacology       Date:  2022-07-14       Impact factor: 8.294

3.  Generational Effects of Opioid Exposure.

Authors:  Katherine E Odegaard; Gurudutt Pendyala; Sowmya V Yelamanchili
Journal:  Encyclopedia (Basel, 2021)       Date:  2021-01-18

4.  Self-regulation and emotional reactivity in infants with prenatal exposure to opioids and alcohol.

Authors:  Kathryn G Beauchamp; Jean Lowe; Ronald M Schrader; Shikhar Shrestha; Crystal Aragón; Natalia Moss; Julia M Stephen; Ludmila N Bakhireva
Journal:  Early Hum Dev       Date:  2020-07-02       Impact factor: 2.079

Review 5.  Prenatal opioid exposure and vulnerability to future substance use disorders in offspring.

Authors:  Yaa Abu; Sabita Roy
Journal:  Exp Neurol       Date:  2021-01-29       Impact factor: 5.330

6.  Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7.

Authors:  Sara Shum; Nina Isoherranen
Journal:  AAPS J       Date:  2021-01-12       Impact factor: 4.009

Review 7.  Neuroimaging in infants with prenatal opioid exposure: Current evidence, recent developments and targets for future research.

Authors:  Rupa Radhakrishnan; Gregory Grecco; Kellen Stolze; Brady Atwood; Samuel G Jennings; Izlin Z Lien; Andrew J Saykin; Senthilkumar Sadhasivam
Journal:  J Neuroradiol       Date:  2020-10-13       Impact factor: 3.447

8.  SPR Perspectives: scientific opportunities in the Environmental influences on Child Health Outcomes Program.

Authors:  Megan E Romano; Jessie P Buckley; Amy J Elliott; Christine C Johnson; Nigel Paneth
Journal:  Pediatr Res       Date:  2021-05-25       Impact factor: 3.953

9.  The NIH ECHO Program: investigating how early environmental influences affect child health.

Authors:  Carol J Blaisdell; Christina Park; Manjit Hanspal; Mary Roary; S Sonia Arteaga; Susan Laessig; Erin Luetkemeier; Matthew W Gillman
Journal:  Pediatr Res       Date:  2021-06-15       Impact factor: 3.953

10.  Infant neurodevelopmental outcomes of prenatal opioid exposure and polysubstance use.

Authors:  Madelyn H Labella; Rina D Eiden; Alexandra R Tabachnick; Tabitha Sellers; Mary Dozier
Journal:  Neurotoxicol Teratol       Date:  2021-06-08       Impact factor: 4.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.